Background and Aims: Frailty is defined as a syndrome of physiological decline in late life. In patients with cirrhosis, the dysregulation of both catabolic and anabolic muscular pathways S690 Journal of Hepatology 2020 vol. 73 | S653–S915 cause an increased risk of anticipated sarcopenia and frailty. Our goal is to evaluate the effects of a 3 g/die β-hydroxy-β-methylbutyrate (HMB) supplementation for twelve weeks (T1) on muscular mass and performance status in patients with cirrhosis. Method: Clinical history and blood parameters were collected for each patient at the beginning of the study (T0). Furthermore, not only cognitive (Mini Mental State Examination, Psychometric Hepatic Encephalopathy Score, Animal Naming Test) and physical tests (Six Minute Walking Test, Five Chair Stand, Hand Grip Test) but also anthropometric measurements (using“Quadriceps femoris ultra- sound” and Bioimpedentiometry) and Liver Frailty Index (LFI) was performed. Patients were randomized into a treatment group (3 g/die HMB supplementation for 12 weeks) and a control group (3 g/die sorbitol supplementation for 12 weeks). Both groups received nutritional counseling and indications of physical activity to carry out during the treatment period. At the end of the 12 weeks (T1) all the tests and measurements performed at T0 were repeated and the resulting data compared in each patient. Results: 23 cirrhotic patients have been enrolled at present, 14 of the HMB Group and 9 of the Placebo Group. Patients receiving HMB showed a statistically significant improvement in muscular perform- ance at FCS ranging from 14.5 (±5.4 DS) sec to 11.6 (±2.7 DS) sec, at 6MWT rising from 346.8 (±66 DS) m to 416 (±57 DS) m and LFI, decreasing from 4.0 (±0.4 DS) to 3.7 (±0.4 DS) with p value = 0,008. No significant variation between T0 and T1 were reported in patients assigned to the control group. Conclusion: The preliminary results of this controlled randomized study suggest the efficacy of HMB supplementation in enhancing muscular performance and subsequently reducing frailty in cirrhotic patients.
Bruni, A., Lattanzi, B., Molfino, A., Muscaritoli, M., Di Cola, S., Fabrini, N., et al. (2020). Preliminary results of the effects of beta-hydroxy-beta-methylbutyrate supplementation in patients with liver cirrhosis: a randomized controlled pilot study. JOURNAL OF HEPATOLOGY, 73, 2-2 [10.1016/s0168-8278(20)31840-7].
Preliminary results of the effects of beta-hydroxy-beta-methylbutyrate supplementation in patients with liver cirrhosis: a randomized controlled pilot study
Bruni, Angelo;
2020
Abstract
Background and Aims: Frailty is defined as a syndrome of physiological decline in late life. In patients with cirrhosis, the dysregulation of both catabolic and anabolic muscular pathways S690 Journal of Hepatology 2020 vol. 73 | S653–S915 cause an increased risk of anticipated sarcopenia and frailty. Our goal is to evaluate the effects of a 3 g/die β-hydroxy-β-methylbutyrate (HMB) supplementation for twelve weeks (T1) on muscular mass and performance status in patients with cirrhosis. Method: Clinical history and blood parameters were collected for each patient at the beginning of the study (T0). Furthermore, not only cognitive (Mini Mental State Examination, Psychometric Hepatic Encephalopathy Score, Animal Naming Test) and physical tests (Six Minute Walking Test, Five Chair Stand, Hand Grip Test) but also anthropometric measurements (using“Quadriceps femoris ultra- sound” and Bioimpedentiometry) and Liver Frailty Index (LFI) was performed. Patients were randomized into a treatment group (3 g/die HMB supplementation for 12 weeks) and a control group (3 g/die sorbitol supplementation for 12 weeks). Both groups received nutritional counseling and indications of physical activity to carry out during the treatment period. At the end of the 12 weeks (T1) all the tests and measurements performed at T0 were repeated and the resulting data compared in each patient. Results: 23 cirrhotic patients have been enrolled at present, 14 of the HMB Group and 9 of the Placebo Group. Patients receiving HMB showed a statistically significant improvement in muscular perform- ance at FCS ranging from 14.5 (±5.4 DS) sec to 11.6 (±2.7 DS) sec, at 6MWT rising from 346.8 (±66 DS) m to 416 (±57 DS) m and LFI, decreasing from 4.0 (±0.4 DS) to 3.7 (±0.4 DS) with p value = 0,008. No significant variation between T0 and T1 were reported in patients assigned to the control group. Conclusion: The preliminary results of this controlled randomized study suggest the efficacy of HMB supplementation in enhancing muscular performance and subsequently reducing frailty in cirrhotic patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
